This potentially lethal disorder is associated with significant metabolic comorbidities such as central obesity, insulin resistance, and diabetes.[2] Upon activation of the hypothalamic–pituitary–adrenal (HPA) axis, corticotropin‐releasing hormone (CRH) and arginine vasopressin (AVP) are released from the hypothalamic paraventricular nucleus (PVN). Here, AVP is linked to Abdominal obesity.